Allergan's Botox still a physician favorite for migraine despite CGRP push: analyst

21st February 2020 Uncategorised 0

With CGRP drugs on the rise in the preventive migraine market, old stalwarts like Allergan’s Botox are feeling the pinch from the new competition. But a new survey says neurologists may not be so quick to give up on Botox––and that could be another win for AbbVie on the eve of its Allergan merger.

More: Allergan's Botox still a physician favorite for migraine despite CGRP push: analyst
Source: fierce